

Fermenta Biotech Limited (formerly known as DIL Limited)

CIN: L99999MH1951PLC008485

Regd. Office: A - 1501, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (W) - 400 610, Maharashtra, India.

Tel. : +91-22-6798 0888 Fax. : +91-22-6798 0899

Email : info@fermentabiotech.com, Website. : www.fermentabiotech.com



Ref: F.No.:49

January 20, 2022

Corporate Relations,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai – 400 001

Ref: Scrip Code: 506414

Dear Sirs,

Subject: Intimation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 regarding licensing of proprietary biocatalytic technology for synthesis of Molnupiravir and supply of enzyme.

Pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby inform you the following:

The Company has signed an Agreement for License of Technology and Supply of Enzyme on January 20, 2022 ("Agreement") with Aurigene Pharmaceutical Services Limited (APSL), a step down subsidiary of Dr. Reddy's Laboratories Limited (DRL) ["Agreement"] whereby the Company will exclusively license its proprietary biocatalytic technology for synthesis of Molnupiravir and supply its enzyme, Candida Antarctica B Lipase (CAL B), to APSL. APSL will exclusively procure the enzyme from FBL.

A copy of the press release in this regard is enclosed herewith.

This is for your information and records.

Thanking you,

Yours faithfully,

For **Fermenta Biotech Limited**

A handwritten signature in blue ink, appearing to read 'Srikant N. Sharma', is written over a horizontal line.

Srikant N. Sharma

Company Secretary

CS Membership No: F3617

Encl. As above

Factory : Village Takoli, P.O. Nagwain,
Dist. Mandi - 175 121, Himachal Pradesh, India.
Tel. : +91-1905-287246 / 48 / 49
Fax: +91-1905-287250
Email: info@fermentabiotech.com
Website: www.fermentabiotech.com

Factory : Z - 109 B & C, SEZ II, Dahej,
Taluka - Vagara, Dist. Bharuch - 392 130,
Gujarat, India.
Tel. : +91-2641-291440 / 444
Email: info@fermentabiotech.com
Website: www.fermentabiotech.com



Press Release

Fermenta Biotech Limited exclusively licenses its proprietary enzymatic technology for manufacturing Molnupiravir to Aurigene Pharmaceutical Services Limited

Fermenta has signed a Definitive Agreement with Aurigene, a stepdown subsidiary of Dr Reddy's Laboratories Limited

Mumbai, 20 January 2022:

Fermenta Biotech Limited (FBL) today announced that it has signed a Definitive Agreement with Aurigene Pharmaceutical Services Limited (APSL), a stepdown subsidiary of Dr Reddy's Laboratories Limited (DRL). In this arrangement, FBL will exclusively license its proprietary biocatalytic technology for synthesis of Molnupiravir and supply its enzyme Candida Antarctica B Lipase (CAL B) to APSL, and APSL will exclusively procure the enzyme from FBL. Molnupiravir API manufactured by APSL will be utilized by DRL for its formulation. Additionally, APSL can also supply the API manufactured through this technology to other formulators of Molnupiravir, a COVID-19 drug that has recently received emergency use approval from the Food and Drugs Authority and Drugs Controller General of India.

This development follows FBL's announcement of filing patents for its novel technology for synthesizing Molnupiravir in April 2021. Subsequently, the process has been further optimized at the laboratory scale, with demonstrations being successfully conducted at APSL's R&D center in Hyderabad. FBL's biocatalytic technology possesses unique advantages such as enzyme recyclability, optimum solvent recovery and improved process efficiency.

Prashant Nagre, Managing Director, FBL, commented, "Our technology, based on green chemistry, is one of the first of its kind in the world, enabling sustainable and scalable manufacture of Molnupiravir. Additionally, through our expertise in enzymatic solutions, we also bring in cost efficiency by leveraging our in-house enzyme. We are proud to play a role in our collective fight against COVID-19 by making this drug more affordable."



About Fermenta Biotech Ltd. (FBL):

Founded in 1951 and headquartered in Thane, Maharashtra, Fermenta Biotech Limited (FBL) is a pioneer in immobilized enzyme technology with the mission to contribute to the emerging transformation of Biocatalysis. The enzyme manufacturing unit in Kullu, Himachal Pradesh and the Department of Biotechnology (DBT) approved R&D facility in Thane have consistently developed and sustained FBL's leadership in providing advanced enzyme technologies. FBL is a pioneer in the development and production of fermentation-based Penicillin G Amidase enzyme (PGA) and commercialized immobilized enzymes in India. Further, FBL also manufactures CAL B Lipase for a variety of applications from pharmaceuticals, fine chemicals, food and fragrance, leather as well as biodiesel industry. Additionally, FBL is one of the leading manufacturers of Vitamin D3 globally. For more information about the Company and its businesses, please visit our website www.fermentabiotech.com

Safe Harbor:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

For Fermenta Biotech Limited

Name : Mr. Prashant Nagre
Designation : Managing Director
Email ID. : prashant.nagre@fermentabiotech.com